The significant violations included failure to have adequate written procedures for the receipt, identification, testing and handling of raw materials

Prasad said there was a need for the government to focus on and invest more in primary healthcare

An improvement in exports to the US, the key market for Indian drug manufacturers, drove the growth in overall exports from India

Sun Pharma Q2 results: The drugmaker, which earns 37 per cent of its business from the US market, earned Rs 2,389.77 crore from the sale of formulations in the US in Q2FY20 against Rs 2397 crore in the corresponding quarter of the previous year

Lupin's net sales for the quarter stood at Rs 4,296 crore, an increase of 10.4 per cent compared to Rs 3,890 crore in the Q2FY19. The company posted a net loss of Rs 127 crore (after exceptional items) in Q2FY20, compared to Rs 266 crore net profit during the same quarter of the previous year

Lupin Q2 results: Consolidated revenue from operations of the pharma major increased 10.3 per cent year-on-year (YoY) to Rs 4,359.7 crore in Q2FY20 as against Rs 3,951 crore in Q2FY19

Most violations relate to rectifiable documentation, data maintenance, batch-wise consistent production quality, data on supply chain, stability issues, microbial contamination and quality checks

After hitting intra day high of Rs 263.70, Biocon stock saw profit-booking and fell 3.11% to Rs 355 on BSE

The USFDA warning letter will not affect the existing business of Cadila Healthcare in the US and the existing product supplies from the Moraiya facility will continue

Cadila Healthcare share which opened at Rs 257 against previous close of Rs 255.30 hit an intra day high of Rs 260.6 (2.08%)

Hikal share price gained up to 9.51% to Rs 131.90 compared to the previous close of Rs 120.45 on BSE

Robots are changing the world of surgery, including in India

Torrent Pharma recalls drugs from US, Puerto Rico: As per the report, Torrent Pharma Inc is recalling 17,088 bottles of Losartan Potassium /Hydrochlorothiazide tablets, USP 50mg/12.5mg from the same markets.

Cipla share price has lost 2.51% in last 2 days. The US drug regulator carried out inspection from September 16-September 27 in the Goa unit of the firm.  It has subsequently issued form 483 comprising 38 pages which carries 12 observations for the Cipla's Goa facility.

Aurobindo Pharma share price rose 5.13% to Rs 482 compared to the previous close of Rs 458.50 on BSE.

Weighed down by USFDA observations, share price of Aurobindo Pharma declined as much as 20.65 per cent to hit a 52-week low of Rs 450 on the BSE, after opening tad lower at Rs 560 against previous close level of Rs 567.15 on the BSE

The communication also directed the state-level authorities to communicate to the DCGI at the earliest on the action initiated by them.